ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker EM,
Right arrow Articles by Jones, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker EM, , Jr
Right arrow Articles by Jones, M.
Annals of Clinical and Laboratory Science, Vol 28, Issue 5, 300-312
Copyright © 1998 by Association of Clinical Scientists

Articles

Hereditary hemochromatosis

Walker EM Jr, MD Wolfe, ML Norton, SM Walker, and MM Jones

Genetic (hereditary) hemochromatosis is probably the most common autosomal recessive disorder found in white Americans, of whom about 5/1,000 (0.5 percent) are homozygous for the associated gene. The hemochromatosis gene is probably located close to the HLA-A locus on the short arm of chromosome 6. Homozygous individuals may develop severe and potentially lethal hemochromatosis, especially after age 39. Hereditary hemochromatosis involves an increased rate of iron absorption from the gut with subsequent progressive storage of iron in soft organs of the body. Excess iron storage eventually produces pituitary, pancreatic, cardiac, and liver dysfunction and death may result from cardiac arrhythmias, congestive heart failure, and/or hepatic failure or cancer. Early diagnosis can prevent these excess iron-induced problems. Iron overload owing to HLA-linked hereditary hemochromatosis can be distinguished from other causes of hemochromatosis by liver biopsies and interpretations. Patients at risk for genetic hemochromatosis should be screened, identified, and treated as early as age 20 to prevent or minimize the deadly complications of hemochromatosis. Population screening should include measurements of serum iron concentration, total iron binding capacity (TIBC), percent saturation of transferrin, and serum ferritin concentrations. Family members of hereditary hemochromatosis patients are at increased risk and should be tested. Screening, identification and early treatment (phlebotomies, sometimes in combination with the use of Desferal or other iron-chelating agents) may help prevent or reduce iron-related organ damage and premature deaths. Early diagnosis and treatment will reduce the population of aging individuals with severe, complicated hemochromatosis and dramatically reduce medical costs (billions of U.S. dollars per annum) associated with the management of this disease.


This article has been cited by other articles:


Home page
 Annals of Clinical & Laboratory ScienceHome page
E. M. Walker Jr., C. P. Epling, C. Parris, S. Cansino, P. Ghosh, D. H. Desai, R. G. Morrison, G. L. Wright, P. Wehner, E. I. Mangiarua, et al.
Acetaminophen Protects Against Iron-Induced Cardiac Damage in Gerbils
Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 22 - 33.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. E. Vanderveen
Gap Analysis Guidelines for Assessing Acute, Chronic, and Lifetime Exposures to High Levels of Various Nutrients
J. Nutr., February 1, 2006; 136(2): 514S - 519S.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. M. Sanchez, G. B. Schreiber, J. Bethel, P. R. McCurdy, S. A. Glynn, A. E. Williams, R. Gilcher, and for the Retrovirus Epidemiology Donor Study
Prevalence, Donation Practices, and Risk Assessment of Blood Donors With Hemochromatosis
JAMA, September 26, 2001; 286(12): 1475 - 1481.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Association of Clinical Scientists.